EUVIMEDOpdag EUVIMED
Klinische StudieMultizentrische StudieOpen access

Development of a Comprehensive Decision Support Tool for Chemotherapy-Cycle Prescribing: Initial Usability Study

Sanna Iivanainen iD, Reetta Arokoski iD, Santeri Mentu iD, Laura Lang iD, Jussi Ekström iD, Henri Virtanen iD, Vesa Kataja iD, Jussi Pekka Koivunen iD

JMIR Formative Research · 2025

DOI: 10.2196/62749 ↗

At a glance

Klinische Studie in JMIR Formative Research, 2025. Written by Sanna Iivanainen and 7 co-authors. Institution: Department of Oncology and Radiotherapy, Oulu University Hospital, Kajaanintie 50, Oulu, 90220, Finland, 358 83153038. Major MEDLINE topics: Antineoplastic Agents, Colorectal Neoplasms, Decision Support Systems, Clinical. 24 references. The full text is freely available in PubMed Central.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Background

Chemotherapy cycle prescription is generally carried out through a multistep manual process that is prone to human error. Clinical decision support tools can provide patient-specific assessments that support clinical decisions, improve prescribing practices, and reduce medication errors.

Objective

We hypothesized that a knowledge-based, patient-derived, evidence-directed decision support tool consisting of multiple modules focusing on the core duties preceding chemotherapy-cycle prescription could result in a more cost-effective and error-free approach and streamline the workflow.

Methods

A 1-arm, multicenter, prospective clinical trial (“Follow-up of Cancer Patients Receiving Chemotherapy or Targeted Therapy by Electronic Patient Reported Outcomes-tool” [ECHO] 7/2019-1/2021; NCT04081558) was initiated to investigate the tool. The most important inclusion criteria were the presence of colorectal cancer (CRC) treated with oxaliplatin-based chemotherapy, age ≥18 years, Eastern Cooperative Oncology Group [ECOG] performance score of 0 to 2, and internet access. A decision support tool that included digital symptom monitoring, a laboratory value interface, and treatment schedule integration for semiautomated chemotherapy cycle prescribing was integrated into the care pathway. Performance was assessed by the percentage of chemotherapy cycles with sent and completed symptom questionnaires, while perceptions of health care professionals (HCPs) on the feasibility of the approach were collected through a 1-time semistructured interview.

Results

The ECHO trial included 43 patients with CRC treated with doublet or triplet chemotherapy in an adjuvant or metastatic setting. Altogether, 843 electronic patient-reported outcome (ePRO) symptom questionnaires were completed. Of the 15 recorded symptoms, fatigue (n=446, 52.9%) and peripheral neuropathy (n=429, 50.9%) were reported most often, while 137 grade 3 to 4 symptoms were recorded, of which diarrhea (n=5, 4%) and peripheral neuropathy (n=4, 3%) were the most common. During the study, 339 chemotherapy cycles were prescribed, and for the 77% (n=262) of new chemotherapy cycles, ePRO questionnaire data were available within preset limits (completed within 3 days prior to chemotherapy scheduling) while 65% of the cycles (n=221) had symptom questionnaire grading at ≤1%, and 67% of the cycles (n=228) had laboratory values in a preset range. The recommendations by the tool for a new chemotherapy cycle were tier 1 (green; meaning “go”) in 145 (42.8%) of the cycles, tier 2 (yellow; “evaluate”) in 83 (25%), and tier 3 (red; “hold”) in 111 (32.7%). HCPs (n=3) were interviewed with a questionnaire (comprising 8 questions), revealing that they most valued the improved workflow, faster patient evaluation, and direct messaging option.

Conclusions

In this study, we investigated the feasibility of a decision support system for chemotherapy-cycle pre-evaluation and prescription that was developed for the prospective ECHO trial. The study showed that the functionalities of the investigated tool were feasible and that an automated approach to chemotherapy-cycle prescription was possible for nearly half of the cycles.

Subjects

MeSH terms (MEDLINE)

Antineoplastic AgentsColorectal NeoplasmsDecision Support Systems, ClinicalAdultAgedFemaleHumansMaleMiddle AgedPatient Reported Outcome MeasuresProspective StudiesSurveys and Questionnaires

Author keywords

cancerchemotherapydecision support systemePROelectronic patient-reported outcome

Substances

Antineoplastic Agents

Authors and institutions

  • Department of Oncology and Radiotherapy, Oulu University Hospital, Kajaanintie 50, Oulu, 90220, Finland, 358 83153038.
  • Kaiku Health Oy, Helsinki, Finland.

ORCID profiles: Sanna Iivanainen, Reetta Arokoski, Santeri Mentu, Laura Lang, Jussi Ekström, Henri Virtanen, Vesa Kataja, Jussi Pekka Koivunen

Cite

APA

Iivanainen, S., Arokoski, R., Mentu, S., Lang, L., Ekström, J., Virtanen, H., Kataja, V., & Koivunen, J. P. (2025). Development of a Comprehensive Decision Support Tool for Chemotherapy-Cycle Prescribing: Initial Usability Study. JMIR Formative Research. https://doi.org/10.2196/62749

Vancouver

Iivanainen S, Arokoski R, Mentu S, Lang L, Ekström J, Virtanen H, et al. Development of a Comprehensive Decision Support Tool for Chemotherapy-Cycle Prescribing: Initial Usability Study. JMIR Formative Research. 2025. doi:10.2196/62749

BibTeX
@article{Iivanainen2025,
  author = {Iivanainen, Sanna and Arokoski, Reetta and Mentu, Santeri and Lang, Laura and Ekström, Jussi and Virtanen, Henri and Kataja, Vesa and Koivunen, Jussi Pekka},
  title = {Development of a Comprehensive Decision Support Tool for Chemotherapy-Cycle Prescribing: Initial Usability Study},
  journal = {JMIR Formative Research},
  year = {2025},
  doi = {10.2196/62749}
}
Start for free →